Table 3 Effect of different treatments on PI3K/AKT/mTOR signaling pathway gene expression of Caco-2.
Tested gene | Untreated cells | Trial 4 | Trial 15 | Trial 16 | Trial 20 |
|---|---|---|---|---|---|
PI3K | 833.6 ± 10.3c | 33.69 ± 3.9b | 6.1 ± 1.03a | 10.2 ± 1.38a | 8.05 ± 2.03a |
P53 | 0.21 ± 0.003a | 11.58 ± 1.77b | 44.16 ± 5.7c | 15.86 ± 3.88b | 24.2 ± 7.38b |
BCl2 | 165.3 ± 1.59e | 105.98 ± 14.6d | 0.89 ± 0.002a | 54.32 ± 12.3c | 8.93 ± 0.041b |
mTOR | 850.8 ± 23.19e | 437.8 ± 16.8d | 6.35 ± 0.78a | 157.43 ± 13.78c | 21.58 ± 1.7b |
AKT | 134.71 ± 8.97e | 33.45 ± 2.47c | 0.981 ± 0.02a | 43.56 ± 1.78d | 21.3 ± 4.78b |
PGC1α | 209.3 ± 3.12e | 50.36 ± 12c | 2.78 ± 0.07a | 98.3 ± 11.89d | 9.68 ± 0.1b |
VEGF | 22.3 ± 0.98d | 8.73 ± 0.08b | 3.78 ± 0.23a | 14.65 ± 1.9c | 7.89 ± 0.08b |
PTEN | 0.125 ± 0.005a | 22.39 ± 5.71b | 156.3 ± 3.69d | 55.69 ± 8.9c | 43.89 ± 12.3c |